Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.
Awais
Ahmed
A
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, USA.
Tam
Constantine S
CS
Kontoyiannis
Dimitrios
D
Ferrajoli
Alessandra
A
Duvic
Madeleine
M
Cortes
Jorge
J
Keating
Michael J
MJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000382:microbiology*; D019910:Mycobacterium marinum / Q000302:isolation & purification*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D017192:Skin Diseases, Bacterial / Q000382:microbiology*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide